Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CanadaBis CapitalTSXV:CANB EV-to-EBITDA is 17.82 as of Aug. 18, 2026, which is 170% above its 10-year median of 6.59. The stock has 6 warning signs investors should review. Among 734 Drug Manufacturers companies, CanadaBis Capital ranks worse than 61.85% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CanadaBis Capital's enterprise value is C$8.79 Mil.
CanadaBis Capital's EBITDA for the trailing twelve months (TTM) ended in Oct. 2025 was C$0.49 Mil. Therefore, CanadaBis Capital's EV-to-EBITDA for today is 17.82.
The historical rank and industry rank for CanadaBis Capital's EV-to-EBITDA or its related term are showing as below:
TSXV:CANB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -276.21 Med: 6.59 Max: 24.75
Current: 17.82
During the past 10 years, the highest EV-to-EBITDA of CanadaBis Capital was 24.75. The lowest was -276.21. And the median was 6.59.
TSXV:CANB's EV-to-EBITDA is ranked worse than 61.85% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs TSXV:CANB: 17.82
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
CanadaBis Capital (TSXV:CANB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CanadaBis Capital's PE Ratio (TTM) for today is calculated as:
CanadaBis Capital's share price for today is C$0.015.
CanadaBis Capital's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Oct. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for CanadaBis Capital's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:CANB vs GCAN, STEK, GRPS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, CanadaBis Capital's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CanadaBis Capital EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CanadaBis Capital's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CanadaBis Capital's EV-to-EBITDA falls into.
CanadaBis Capital's current Enterprise Value is C$8.79 Mil.
CanadaBis Capital's EBITDA for the trailing twelve months (TTM) ended in Oct. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CanadaBis Capital (TSXV:CANB) has a EV-to-EBITDA of 17.82 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CanadaBis Capital. This is 170% above median its historical median of 6.59. According to the industry distribution chart, CanadaBis Capital ranks #454 out of 734 companies in the Drug Manufacturers industry, placing it in the top 61.9%.
Is CanadaBis Capital's EV-to-EBITDA too high?
CanadaBis Capital's current EV-to-EBITDA of 17.82 is 170% above median its 10-year median of 6.59. The Drug Manufacturers industry median EV-to-EBITDA is 13.44. CanadaBis Capital's value of 17.82 is 32.6% above this industry median. Based on the distribution chart, CanadaBis Capital ranks #454 out of 734 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does CanadaBis Capital's EV-to-EBITDA compare to GCAN and STEK?
According to the Drug Manufacturers industry distribution chart, CanadaBis Capital ranks #454 out of 734 companies for EV-to-EBITDA. This places CanadaBis Capital in the lower half of its industry. The industry median EV-to-EBITDA is 13.44. CanadaBis Capital's value of 17.82 is 32.6% above this benchmark. While the company's 10-year median is 6.59 vs. the industry median of 13.44, CanadaBis Capital has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CanadaBis Capital's current EV-to-EBITDA of 17.82 is 32.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on CanadaBis Capital. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CanadaBis Capital's current EV-to-EBITDA is 17.82, which is 170% above median its own 10-year median of 6.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CanadaBis Capital stock overvalued right now?
CanadaBis Capital (TSXV:CANB) has a current EV-to-EBITDA of 17.82. The stock's GF Value™ is C$0.07, compared to a current price of C$0.02 — trading 78.6% below its estimated fair value. The current EV-to-EBITDA is 17.82, which is 170% above median its 10-year median of 6.59 and 32.6% above the Drug Manufacturers industry median of 13.44. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For CanadaBis Capital (TSXV:CANB), the current EV-to-EBITDA is 17.82 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CanadaBis Capital Inc is a vertically integrated cannabis company. The firm engages in the production and sale of recreational cannabis. Its product line consists of Stigma Roots. It operates in three segments: wholesale, retail, and extract. The wholesale segment cultivates and distributes cannabis and cannabis products to and through, provincial liquor and cannabis boards. Retail segment involves sale of cannabis and cannabis-related products to end consumers on-premises owned and operated by the Company. Extract segment provides cannabinoid extraction services to other licensed producers. The company generates maximum of its revenue from Extract Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:CANB has been successfully added to your 
